In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Robert Storey
Speaker
Robert Storey
Robert Storey Robert Storey

University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)

Specialities : Interventional Cardiology , Acute Coronary Syndromes

Professor Robert Storey is Professor of Cardiology at the University of Sheffield, Sheffield, UK, where he has headed a thrombosis research group since 2002 and is director of the Cardiovascular Research Unit. He is also Academic Director and honorary Consultant Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust. He has a special interest in the management of ischaemic heart disease, including acute coronary syndromes and coronary intervention. He was Chair of the ESC Working Group on Thrombosis 2012-14 and has served on several ESC guidelines task forces (chronic coronary syndromes 2019, NSTE ACS 2011 and 2015, dyslipidaemias 2011). He is/has been a member of numerous executive/steering committees for clinical trials in patients with ischaemic heart disease, such as PLATO, PEGASUS-TIMI 54, AUGUSTUS and COMPLETE.

28 presentations from this speaker

Acute coronary syndrome and atrial fibrillation: triple or double anticoagulation therapy?

Event : Webinar 2019

  • Session : EHRA Webinars 2019
  • Speaker : RA Byrne (Dublin,IE), J Steffel (Zurich,CH), RF Storey (Sheffield,GB)

AF patients with ACS: the evolving landscape.

Event : EHRA 2019

  • Session : Optimizing stroke prevention with NOACs: focus on Atrial Fibrillation (AF) patients with concomitant Acute Coronary Syndrome (ACS)
  • Speaker : RF Storey (Sheffield,GB)
  • Sponsored by BMS/Pfizer Alliance

Intensive platelet inhibition - Have we reached the ceiling or are there options for further development?

Event : ESC Congress 2019

  • Session : Intensive platelet inhibition in acute coronary syndromes - Where are we a decade after PLATO study results? (EBAC Accredited)
  • Speaker : L Wallentin (Uppsala,SE), R Mehran (New York,US), RF Storey (Sheffield,GB), C Cannon (Boston,US), S James (Uppsala,SE)
  • Supported by an unrestricted educational grant from AstraZeneca

Manipulating the platelet - Successes and failures

Event : ESC Congress 2019

  • Session : Intensive platelet inhibition in acute coronary syndromes - Where are we a decade after PLATO study results? (EBAC Accredited)
  • Speaker : RF Storey (Sheffield,GB)
  • Supported by an unrestricted educational grant from AstraZeneca

Optimising NOAC management in atrial fibrilllation and ACS/PCI - Clinical practice perspective

Event : ESC Congress 2019

  • Session : Optimising non-vitamin K antagonist oral anticoagulant (NOAC) management in atrial fibrillation and acute coronary syndrome (ACS)/percutaneous coronary intervention (PCI) - Clinical practice perspective
  • Speaker : RF Storey (Sheffield,GB), R Lopes (Durham,US), S Halvorsen (Oslo,NO)
  • Sponsored by The Bristol-Myers Squibb/Pfizer Alliance

Panel discussion: use of reversal agents in practice

Event : ESC Congress 2019

  • Session : DOAC-related bleeding: what every cardiologist needs to know
  • Speaker : RF Storey (Sheffield,GB)
  • Organised by Medscape Education, supported with an educational grant from Portola Pharmaceuticals, Inc.

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - CONTRA.

Event : Acute Cardiovascular Care 2018

  • Session : Controversies on anticoagulants post-MI antithrombotic treatment
  • Speaker : RF Storey (Sheffield,GB)

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal CONTRA.

Event : Acute Cardiovascular Care 2018

  • Session : Controversies on anticoagulants post-MI antithrombotic treatment
  • Speaker : RF Storey (Sheffield,GB)

P2Y12 inhibitors in NSTE-ACS - Chairperson conclusion.

Event : ESC Congress 2018

  • Session : Dual antiplatelet therapy and PCI - Important controversies
  • Speaker : RF Storey (Sheffield,GB)

Practical tips and tricks based on the 2018 European Consensus Document: case examples.

Event : ESC Congress 2018

  • Session : 2018 Joint European Consensus Document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions
  • Speaker : RF Storey (Sheffield,GB)

The future of DAPT

Event : ESC Congress 2018

  • Session : Antiplatelet therapy in PCI
  • Speaker : RF Storey (Sheffield,GB)

Antithrombotic therapy in secondary prevention - How long and how strong?

Event : Webinar 2017

  • Session : EAPC Webinars 2017
  • Speaker : H Bueno (Madrid,ES), SD Kristensen (Aarhus N,DK), RF Storey (Sheffield,GB)

Antithrombotics and stroke - Acute phase, secondary prevention, primary prevention

Event : ESC Congress 2017

  • Session : What cardiologists need to know about stroke
  • Speaker : RF Storey (Sheffield,GB)
  • Council on Stroke

Future perspectives for antithrombotic strategy after acute coronary syndromes

Event : ESC Congress 2017

  • Session : P2Y12 inhibitors in acute coronary syndromes
  • Speaker : RF Storey (Sheffield,GB)

Long-term ticagrelor: lessons from PEGASUS.

Event : Acute Cardiovascular Care 2016

  • Session : Secondary prevention after acute coronary syndromes
  • Speaker : RF Storey (Sheffield,GB)
  • Joint session with the European Association of Preventive Cardiology (EAPC)

State of the art in platelets and thrombosis.

Event : ESC Congress 2016

  • Session : Platelets and thrombosis
  • Speaker : RF Storey (Sheffield,GB)

A case of NSTEMI at intermediate risk: when to transfer to a cath-lab center and how-long to monitor - What do the Guidelines say?

Event : ESC Congress 2015

  • Session : 2015 ESC guidelines on NSTE-ACS: implementation in daily practice
  • Speaker : RF Storey (Sheffield,GB)

Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study

Event : ESC Congress 2015

  • Session : Platelets and antiplatelets therapy IV
  • Speaker : RF Storey (Sheffield,GB)

Differentiating anti-platelet therapies: pharmacological evidence. Discussion.

Event : ESC Congress 2015

  • Session : Dual anti-platelet therapy in 2015 – Reviewing the evidence
  • Speaker : RF Storey (Sheffield,GB)
  • Organised by The Sahlgrenska Academy - Goteborg University Course Director: Karl Swedberg Supported by an unrestricted educational grant from AstraZeneca

The evolving acute coronary thrombus; a role for erythrocytes?

Event : ESC Congress 2015

  • Session : In-depth characterisation of thrombosis in myocardial infarction
  • Speaker : RF Storey (Sheffield,GB)

Discussion - Thienopyridines and ticagrelor.

Event : ESC Congress 2014

  • Session : Antiplatelet therapy in high-risk patients with acute coronary syndromes – Current evidence and future directions
  • Speaker : RF Storey (Sheffield,GB)
  • Organised by The Sahlgrenska Academy - Goteborg University / Course Director: Karl Swedberg / Supported by an unrestricted educational grant from AstraZeneca

Prasugrel or ticagrelor in STEMI - what is the best option?

Event : ESC Congress 2014

  • Session : Challenges in antithrombotic treatment of STEMI
  • Speaker : RF Storey (Sheffield,GB)

The prognostic value of CYP2C19 gene polymorphism in ACS patients. The European experience.

Event : ESC Congress 2014

  • Session : Chinese and European perspectives on acute coronary syndrome and hypertension
  • Speaker : RF Storey (Sheffield,GB)

Thienopyridines and ticagrelor – New pharmacological evidence and clinical effects.

Event : ESC Congress 2014

  • Session : Antiplatelet therapy in high-risk patients with acute coronary syndromes – Current evidence and future directions
  • Speaker : RF Storey (Sheffield,GB)
  • Organised by The Sahlgrenska Academy - Goteborg University / Course Director: Karl Swedberg / Supported by an unrestricted educational grant from AstraZeneca

Contra.

Event : ESC Congress 2013

  • Session : Drop the Aspirin.
  • Speaker : RF Storey (Sheffield,GB)

Contra.

Event : ESC Congress 2013

  • Session : Drop the Aspirin.
  • Speaker : RF Storey (Sheffield,GB)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are